Skip to main content
Premium Trial:

Request an Annual Quote

Vicki Sato, Ambion

Premium

People

Bristol-Myers Squibb said this week that it has appointed Vicki Sato to its board of directors.

Sato also sits on the board of Alnylam Pharmaceuticals.

Sato is currently a professor of molecular and cell biology at Harvard University, and previously served as president of Vertex Pharmaceuticals. Prior to this, she was vice president of research at Biogen, a biotechnology firm co-founded by Alnylam co-founder Phillip Sharp.

Products & Services

Ambion recently introduced its mirVana miRNA bioarrays V2, a version of the company's microRNA microarrays that includes probes targeting an exclusive set of 152 newly identified human miRNAs.

The new bioarrays also feature 22 control probes, the company said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.